Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
Introduction: Limited data exist on the cardiovascular effectiveness of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in real-world practice. Methods: We assessed the OW GLP-1 RA effects on vascular risk factors in adults with type 2 diabetes and atherosclerotic cardiovascul...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | American Journal of Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667724002915 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533239292854272 |
|---|---|
| author | Aaron King Xi Tan Neil Dhopeshwarkar Rhonda Bohn Katherine Dea Charles E. Leonard Adam de Havenon |
| author_facet | Aaron King Xi Tan Neil Dhopeshwarkar Rhonda Bohn Katherine Dea Charles E. Leonard Adam de Havenon |
| author_sort | Aaron King |
| collection | DOAJ |
| description | Introduction: Limited data exist on the cardiovascular effectiveness of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in real-world practice. Methods: We assessed the OW GLP-1 RA effects on vascular risk factors in adults with type 2 diabetes and atherosclerotic cardiovascular disease using data from a large-scale US electronic health record database (index date = first prescription of OW GLP-1 RA). Exploratory analyses were performed on patients newly initiating OW GLP-1 RAs with semaglutide, OW GLP-1 RAs without semaglutide, and semaglutide. Changes in vascular risk factors were evaluated by comparing mean measures between the 12-month pre- and post-index periods. Analyses were conducted for all three cohorts and subpopulations including stratified by tercile of baseline vascular risk factor value. Results: In the final cohorts ([1] OW GLP-1 RA including semaglutide: n = 20,084; [2] OW GLP-1 RA excluding semaglutide: n = 16,894; [3] semaglutide: n = 3,435), significant mean reductions (P < 0.001) were observed from baseline to post-index in hemoglobin A1c (%, [1] -1.1; [2] -1.1; [3] -1.2), low-density lipoprotein cholesterol (mg/dL, [1] -6.4; [2] -6.4; [3] -6.9), total cholesterol (mg/dL, [1] -11.0; [2] -11.1; [3] -10.7), triglycerides (mg/dL, [1] -31.8; [2] -31.4; [3] -33.1), systolic blood pressure (mmHg, [1] -1.5; [2] -1.2; [3] -3.1), body weight (kg, [1] -2.7; [2] -2.4; [3] -4.3) and body mass index (kg/m2; [1] -0.9; [2] -0.8; [3] -1.4). Largest reductions were observed in the top tercile. Conclusion: Our data suggest GLP-1 RAs are associated with significant reductions in key vascular risk factors in real-world practice. |
| format | Article |
| id | doaj-art-6c17dc3d0afa499e93ddba3a94e0a949 |
| institution | Kabale University |
| issn | 2666-6677 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Preventive Cardiology |
| spelling | doaj-art-6c17dc3d0afa499e93ddba3a94e0a9492025-01-17T04:52:26ZengElsevierAmerican Journal of Preventive Cardiology2666-66772025-03-0121100922Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular diseaseAaron King0Xi Tan1Neil Dhopeshwarkar2Rhonda Bohn3Katherine Dea4Charles E. Leonard5Adam de Havenon6Baptist Health System Physicians Network, MedFirst Primary Care – Quarry, 430 W Sunset Rd Suite, San Antonio, TX 78209, USANovo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ 08536, USATriNetX, LLC., 125 Cambridgepark Dr #500, Cambridge, MA 02140, USABohn Epidemiology, LLC., 16 Fayette St, Suite 2, Boston, MA 02116, USAStatlog Econometrics Inc., 3 Place Ville Marie, Bureau 400, Montreal, QC H3B 2E3, CanadaDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, 423 Guardian Dr, Philadelphia, PA 19104, USADepartment of Neurology, Center for Brain and Mind Health, Yale University School of Medicine, 100 College St, New Haven, CT 06510, USA; Corresponding author at: Yale University School of Medicine, Department of Neurology, LLCI 912, New Haven, CT 06520, USA.Introduction: Limited data exist on the cardiovascular effectiveness of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in real-world practice. Methods: We assessed the OW GLP-1 RA effects on vascular risk factors in adults with type 2 diabetes and atherosclerotic cardiovascular disease using data from a large-scale US electronic health record database (index date = first prescription of OW GLP-1 RA). Exploratory analyses were performed on patients newly initiating OW GLP-1 RAs with semaglutide, OW GLP-1 RAs without semaglutide, and semaglutide. Changes in vascular risk factors were evaluated by comparing mean measures between the 12-month pre- and post-index periods. Analyses were conducted for all three cohorts and subpopulations including stratified by tercile of baseline vascular risk factor value. Results: In the final cohorts ([1] OW GLP-1 RA including semaglutide: n = 20,084; [2] OW GLP-1 RA excluding semaglutide: n = 16,894; [3] semaglutide: n = 3,435), significant mean reductions (P < 0.001) were observed from baseline to post-index in hemoglobin A1c (%, [1] -1.1; [2] -1.1; [3] -1.2), low-density lipoprotein cholesterol (mg/dL, [1] -6.4; [2] -6.4; [3] -6.9), total cholesterol (mg/dL, [1] -11.0; [2] -11.1; [3] -10.7), triglycerides (mg/dL, [1] -31.8; [2] -31.4; [3] -33.1), systolic blood pressure (mmHg, [1] -1.5; [2] -1.2; [3] -3.1), body weight (kg, [1] -2.7; [2] -2.4; [3] -4.3) and body mass index (kg/m2; [1] -0.9; [2] -0.8; [3] -1.4). Largest reductions were observed in the top tercile. Conclusion: Our data suggest GLP-1 RAs are associated with significant reductions in key vascular risk factors in real-world practice.http://www.sciencedirect.com/science/article/pii/S2666667724002915Cardiovascular diseaseDiabetesGlucagon-like peptide-1 receptor agonistPharmacoepidemiologyReal-worldSemaglutide |
| spellingShingle | Aaron King Xi Tan Neil Dhopeshwarkar Rhonda Bohn Katherine Dea Charles E. Leonard Adam de Havenon Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease American Journal of Preventive Cardiology Cardiovascular disease Diabetes Glucagon-like peptide-1 receptor agonist Pharmacoepidemiology Real-world Semaglutide |
| title | Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease |
| title_full | Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease |
| title_fullStr | Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease |
| title_full_unstemmed | Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease |
| title_short | Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease |
| title_sort | effect of glucagon like peptide 1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease |
| topic | Cardiovascular disease Diabetes Glucagon-like peptide-1 receptor agonist Pharmacoepidemiology Real-world Semaglutide |
| url | http://www.sciencedirect.com/science/article/pii/S2666667724002915 |
| work_keys_str_mv | AT aaronking effectofglucagonlikepeptide1receptoragonistsonvascularriskfactorsamongadultswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease AT xitan effectofglucagonlikepeptide1receptoragonistsonvascularriskfactorsamongadultswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease AT neildhopeshwarkar effectofglucagonlikepeptide1receptoragonistsonvascularriskfactorsamongadultswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease AT rhondabohn effectofglucagonlikepeptide1receptoragonistsonvascularriskfactorsamongadultswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease AT katherinedea effectofglucagonlikepeptide1receptoragonistsonvascularriskfactorsamongadultswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease AT charleseleonard effectofglucagonlikepeptide1receptoragonistsonvascularriskfactorsamongadultswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease AT adamdehavenon effectofglucagonlikepeptide1receptoragonistsonvascularriskfactorsamongadultswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease |